NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference

NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given that α-synuclein has been shown to correlate with worse cognitive function in Alzheimer's disease. Presentation details are as follows: More information about AAIC 2024 can be found at: https://aaic.alz.org/. About NKGen Biotech Statements contained in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Sec ...